All In Biotech

Drug Trial Radar · NCT03255993

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Multiple Doses Study to Evaluate the Tolerability and Pharmacokinetics of SPH3127 in Chinese Healthy People

Last checked: Nov 19, 2026Latest source record: Nov 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Oct 23, 2017

Primary completion

Sep 20, 2018

Study completion Sep 20, 2018

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study was a single center, parallel, randomized, double blind, placebo-controlled phase Ib clinical trial to to evaluate the safety and tolerability and pharmacokinetics of SPH3127 tablet in healthy subjects by increasing multiple dosing

Conditions

  • Hypertension

Interventions

  • SPH3127 50mgDrug

    SPH3127 50mg

  • SPH3127 100mgDrug

    SPH3127 100mg

  • Placebo matching to SPH3127 50mgDrug

    Placebo matching to SPH3127 50mg

  • Placebo matching to SPH3127 100mgDrug

    Placebo matching to SPH3127 100mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Baseline to 13-16 days post last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The capital medical university affiliated Beijing anzhen hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.